EE9800116A - Farmatseutiliselt aktiivsed kinasoliini ühendid - Google Patents
Farmatseutiliselt aktiivsed kinasoliini ühendidInfo
- Publication number
- EE9800116A EE9800116A EE9800116A EE9800116A EE9800116A EE 9800116 A EE9800116 A EE 9800116A EE 9800116 A EE9800116 A EE 9800116A EE 9800116 A EE9800116 A EE 9800116A EE 9800116 A EE9800116 A EE 9800116A
- Authority
- EE
- Estonia
- Prior art keywords
- pharmaceutically active
- quinazoline compounds
- active quinazoline
- compounds
- pharmaceutically
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9521231.2A GB9521231D0 (en) | 1995-10-17 | 1995-10-17 | Pharmaceutically active compounds |
| GBGB9602668.7A GB9602668D0 (en) | 1996-02-09 | 1996-02-09 | Pharmaceutically active compounds |
| GBGB9614386.2A GB9614386D0 (en) | 1996-07-09 | 1996-07-09 | Pharmaceutically active compounds |
| PCT/GB1996/002496 WO1997014686A1 (en) | 1995-10-17 | 1996-10-14 | Pharmaceutically active quinazoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE9800116A true EE9800116A (et) | 1998-10-15 |
Family
ID=27267949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EE9800116A EE9800116A (et) | 1995-10-17 | 1996-10-14 | Farmatseutiliselt aktiivsed kinasoliini ühendid |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5883102A (de) |
| EP (1) | EP0858451A1 (de) |
| JP (1) | JPH11513679A (de) |
| KR (1) | KR19990064276A (de) |
| CN (1) | CN1204327A (de) |
| AR (1) | AR004219A1 (de) |
| AU (1) | AU704133B2 (de) |
| BR (1) | BR9610988A (de) |
| CA (1) | CA2235304A1 (de) |
| CZ (1) | CZ119398A3 (de) |
| EE (1) | EE9800116A (de) |
| HU (1) | HUP9900028A3 (de) |
| IS (1) | IS4715A (de) |
| NO (1) | NO310620B1 (de) |
| NZ (1) | NZ319673A (de) |
| PL (1) | PL326353A1 (de) |
| SK (1) | SK45898A3 (de) |
| TR (1) | TR199800697T2 (de) |
| WO (1) | WO1997014686A1 (de) |
| ZA (1) | ZA968767B (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| SE9702534D0 (sv) * | 1997-07-01 | 1997-07-01 | Astra Pharma Prod | Compounds |
| DE19731783A1 (de) * | 1997-07-24 | 1999-01-28 | Bayer Ag | Verfahren zur Herstellung von N-(5-Amino-2-cyano-4-fluor-phenyl)-sulfonamiden und neue Zwischenprodukte |
| WO1999065494A1 (en) | 1998-06-15 | 1999-12-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| SE9802333D0 (sv) | 1998-06-29 | 1998-06-29 | Astra Pharma Prod | Novel combination |
| CA2342349A1 (en) * | 1998-09-08 | 2000-03-16 | Monsanto Company | Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| SE0000477D0 (sv) * | 2000-02-14 | 2000-02-14 | Astrazeneca Canada Inc | Novel compounds |
| US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| US6534220B2 (en) | 2000-12-29 | 2003-03-18 | 3M Innovative Properties Company | High-boiling electrolyte solvent |
| AP1699A (en) * | 2001-03-21 | 2006-12-26 | Warner Lambert Co | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
| JP4613130B2 (ja) | 2002-08-23 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ベンゾイミダゾールキノリノンおよびそれらの使用 |
| WO2004022554A1 (en) * | 2002-09-07 | 2004-03-18 | Celltech R & D Limited | Quinazolinone derivatives |
| US20040248942A1 (en) * | 2003-02-20 | 2004-12-09 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| WO2005007115A2 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
| US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| EP1735319B1 (de) * | 2004-03-26 | 2017-05-03 | MethylGene Inc. | Histondeacetylase-hemmer |
| US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2006122150A1 (en) * | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| CN103936690B (zh) | 2005-10-25 | 2016-06-08 | 盐野义制药株式会社 | 氨基二氢噻嗪衍生物 |
| TW200804290A (en) * | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| EP1971583B1 (de) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocyclen als modulatoren der indolamin-2,3-dioxygenase |
| WO2007138613A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride |
| WO2007138612A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| EP2147914B1 (de) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Mit zyklischen gruppen substituierte aminodihydrothiazin-derivate |
| DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
| ES2738123T3 (es) | 2008-06-13 | 2020-01-20 | Shionogi & Co | Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa |
| LT2824100T (lt) | 2008-07-08 | 2018-05-10 | Incyte Holdings Corporation | 1,2,5-oksadiazolai, kaip indolamino 2,3-dioksigenazės inhibitoriai |
| JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| BR112012013854A2 (pt) | 2009-12-11 | 2019-09-24 | Shionogi & Co | derivados de oxazina. |
| US20120258961A1 (en) * | 2009-12-24 | 2012-10-11 | Shionogi & Co., Ltd. | 4-amino-1,3-thiazine or oxazine derivative |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| KR101699822B1 (ko) * | 2011-12-21 | 2017-01-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
| AR098343A1 (es) | 2013-11-08 | 2016-05-26 | Incyte Holdings Corp | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa |
-
1996
- 1996-10-14 US US08/793,713 patent/US5883102A/en not_active Expired - Fee Related
- 1996-10-14 SK SK458-98A patent/SK45898A3/sk unknown
- 1996-10-14 HU HU9900028A patent/HUP9900028A3/hu unknown
- 1996-10-14 PL PL96326353A patent/PL326353A1/xx unknown
- 1996-10-14 CZ CZ981193A patent/CZ119398A3/cs unknown
- 1996-10-14 BR BR9610988A patent/BR9610988A/pt unknown
- 1996-10-14 NZ NZ319673A patent/NZ319673A/en unknown
- 1996-10-14 WO PCT/GB1996/002496 patent/WO1997014686A1/en not_active Application Discontinuation
- 1996-10-14 CA CA002235304A patent/CA2235304A1/en not_active Abandoned
- 1996-10-14 CN CN96198998A patent/CN1204327A/zh active Pending
- 1996-10-14 KR KR1019980702767A patent/KR19990064276A/ko not_active Application Discontinuation
- 1996-10-14 EP EP96933545A patent/EP0858451A1/de not_active Withdrawn
- 1996-10-14 EE EE9800116A patent/EE9800116A/xx unknown
- 1996-10-14 TR TR1998/00697T patent/TR199800697T2/xx unknown
- 1996-10-14 JP JP9515588A patent/JPH11513679A/ja active Pending
- 1996-10-14 AU AU72243/96A patent/AU704133B2/en not_active Ceased
- 1996-10-15 AR ARP960104753A patent/AR004219A1/es unknown
- 1996-10-17 ZA ZA968767A patent/ZA968767B/xx unknown
-
1998
- 1998-04-15 IS IS4715A patent/IS4715A/is unknown
- 1998-04-16 NO NO19981710A patent/NO310620B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO981710L (no) | 1998-06-03 |
| BR9610988A (pt) | 1999-04-06 |
| CZ119398A3 (cs) | 1998-09-16 |
| ZA968767B (en) | 1997-04-17 |
| HUP9900028A3 (en) | 1999-11-29 |
| AU704133B2 (en) | 1999-04-15 |
| JPH11513679A (ja) | 1999-11-24 |
| CN1204327A (zh) | 1999-01-06 |
| NZ319673A (en) | 2000-06-23 |
| NO310620B1 (no) | 2001-07-30 |
| SK45898A3 (en) | 1999-01-11 |
| US5883102A (en) | 1999-03-16 |
| CA2235304A1 (en) | 1997-04-24 |
| PL326353A1 (en) | 1998-09-14 |
| WO1997014686A1 (en) | 1997-04-24 |
| EP0858451A1 (de) | 1998-08-19 |
| IS4715A (is) | 1998-04-15 |
| TR199800697T2 (xx) | 1998-07-21 |
| AR004219A1 (es) | 1998-11-04 |
| AU7224396A (en) | 1997-05-07 |
| KR19990064276A (ko) | 1999-07-26 |
| MX9802926A (de) | 1998-08-01 |
| HUP9900028A2 (hu) | 1999-04-28 |
| NO981710D0 (no) | 1998-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE9800116A (et) | Farmatseutiliselt aktiivsed kinasoliini ühendid | |
| DK0817775T3 (da) | Quinazolinderivater | |
| DK0823900T3 (da) | Quinazolinderivater | |
| EE200000438A (et) | Farmatseutiliselt aktiivne morfolinool | |
| IS4848A (is) | Lyfjafræðilega gagnleg efnasambönd | |
| DE59609922D1 (de) | Wirkstoffkombinationen | |
| SE9700660D0 (sv) | Pharmaceutically active compounds | |
| ITMI921865A1 (it) | Glicerofosfoderivati farmacologicamente attivi | |
| SE9704874D0 (sv) | New pharmaceutically active compounds | |
| NO950529D0 (no) | Farmasöytisk aktive diketopiperaziner | |
| NO950530D0 (no) | Farmasöytisk aktive diketopiperaziner | |
| SE9802539D0 (sv) | New pharmaceutically active compounds | |
| GB9502229D0 (en) | Pharmaceutically active compounds | |
| GB9505677D0 (en) | Pharmaceutically active compounds | |
| GB9506274D0 (en) | Pharmaceutically active compounds | |
| GB9502429D0 (en) | Pharmaceutically active compounds | |
| GB9502541D0 (en) | Pharmaceutically active compounds | |
| GB9502668D0 (en) | Pharmaceutically active compounds | |
| GB9502669D0 (en) | Pharmaceutically active compounds | |
| GB9502670D0 (en) | Pharmaceutically active compounds | |
| GB9505076D0 (en) | Pharmaceutically active compounds | |
| GB9501122D0 (en) | Pharmaceutically active compounds | |
| GB9500099D0 (en) | Pharmaceutically active compounds | |
| GB9507641D0 (en) | Pharmaceutically active compounds | |
| GB9509942D0 (en) | Pharmaceutically active compounds |